Everything below concerns Research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-11. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== List of Russian drugs == Aceclidine (Glaucostat, Glaunorm, Glaudin) – parasympathomimetic miotic Acetomepregenol (ACM; mepregenol diacetate; Diamol) – progestin Adapromine (1-(1′-adamantyl)propylamine; Etandan) – adamantane, antiviral, psychostimulant, antidepressant Alafen (alaphen, alafena; amphetamine–β-alanine) – amphetamine derivative, antiserotonergic Arabinopyranosyl-N-methyl-N-nitrosourea (Aranose, Aranoza) – antineoplastic agent Bemethyl (bemitil) – actoprotector Bromantane (Ladasten) – psychostimulant, antidepressant, anxiolytic, adaptogen/actoprotector, immunostimulant Butagest – progestin Carubicin – anthracycline antineoplastic agent Cepentil (tsepentil, N-cyclopentyllysergamide, LCyP) – lysergamide antiserotonergic Chlodantane (chlodantan; ADK-910) – adamantane, adaptogen/actoprotector, immunostimulant Chloracyzine – tricyclic antidepressant, phenothiazine, coronary vasodilator, antianginal Cortifen (cortiphen, kortifen, fencoron) – glucocorticoid, antineoplastic agent Corvalol (corvalolum, Korvalol) – tranquilizer, based on phenobarbital and containing various natural ingredients. In Russia it is sold without prescription, despite the fact that ordinary phenobarbital tablets are sold strictly by doctor's prescription.
Present in most species pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase (also called α-ketoglutarate dehydrogenase) branched-chain α-keto acid dehydrogenase 2-hydroxyphytanoyl-CoA lyase transketolase Present in some species: pyruvate decarboxylase (in yeast) several additional bacterial enzymes The enzymes transketolase, pyruvate dehydrogenase (PDH), and 2-oxoglutarate dehydrogenase (OGDH) are important in carbohydrate metabolism. PDH links glycolysis to the citric acid cycle. OGDH catalyzes the overall conversion of 2-oxoglutarate (alpha-ketoglutarate) to succinyl-CoA and CO2 during the citric acid cycle. The reaction catalyzed by OGDH is a rate-limiting step in the citric acid cycle. The cytosolic enzyme transketolase is central to the pentose phosphate pathway, a major route for the biosynthesis of the pentose sugars deoxyribose and ribose. The mitochondrial PDH and OGDH are part of biochemical pathways that result in the generation of adenosine triphosphate (ATP), which is the main energy transfer molecule for the cell. In the nervous system, PDH is also involved in the synthesis of myelin and the neurotransmitter acetylcholine.
==== On Natural Amino Acids ==== Trp arylation Multiple methods have been reported to achieve tryptophan C–H arylation, where diverse electrophiles such as aryl halides and aryl boronic acids (an example shown below) have been used to transfer the aryl groups. However, current tryptophan C–H arylation reaction conditions remain relatively harsh, requiring organic solvents, low pH and/or high temperatures.
Sources: en.wikipedia.org
=== Conservative === Indicated in patients who have evidence of exposed bone but no evidence of infection. It may not necessarily eliminate all the lesions, but it may provide patients with long term relief. This approach involves a combination of antiseptic mouthwashes and analgesics and the use of teriparatide. Splints may be used to protect sites of exposed necrotic bone.
After the end of the American Civil War, Chicago, Illinois emerged as a major railway center for the distribution of livestock raised on the Great Plains to Eastern markets. Transporting the animals to market from ranches in Texas required herds to be driven up to 1,200 miles (1,900 km) to railheads in Kansas City, Missouri or later to more westerly locations, such as Abilene, Kansas (1867, Kansas Pacific Railway) and Dodge City, Kansas (1872, Santa Fe Railroad), where they were loaded into specialized stock cars and transported live ("on-the-hoof") to regional processing centers. Driving cattle across the plains also caused tremendous weight loss, with some animals dying in transit. Upon arrival at the local processing facility, livestock were slaughtered by wholesalers and delivered fresh to nearby butcher shops for retail sale, smoked, or packed for shipment in barrels of salt. Costly inefficiencies were inherent in transporting live animals by rail, particularly the fact that approximately 60% of the animals' mass is inedible. The death of animals weakened by the long drive further increased the per-unit shipping cost. Meat processors sought a method to ship dressed meats from their Chicago packing plants to eastern markets.
== Recruitment == Finding a potential sperm donor, and motivating him to donate sperm, is referred to as recruitment. A sperm bank can recruit donors by advertising—-often in colleges, in local newspapers, and on the internet. A donor must be a fit and healthy male, normally between 18 and 45 years of age, willing to undergo frequent rigorous testing. The donor must also be willing to donate his sperm so that it can be used to impregnate people who are unrelated to him whom he does not know. Some sperm banks require two screenings and a laboratory screening before a donor is eligible. The donor must agree to relinquish all legal rights to all children who result from his donations. The donor must produce his sperm at the sperm bank, thus enabling the identity of the donor, once proven, to be ascertained. Some sperm banks have been accused of heightism due to minimum height requirements.
== Research and career == In 2000 Pohl joined the faculty at Iowa State University. She spent twelve years in Iowa, eventually being made Wilkinson Professor of Chemistry and Biomedical Engineering. In 2008 she founded LuCELLa Biosciences, a spin-out company who specialise in the custom synthesis of carbohydrates. Pohl joined Indiana University Bloomington in 2012, where she was made the Professor and Joan & Marvin Carmack Chair. Pohl is interested in the synthesis and characterisation of sugars in an effort to better understand their role in biological function. By better understanding the interactions of carbohydrates, Pohl believes that she will be able to rationally design vaccinations and other therapies. She demonstrated an oligosaccharide synthesis process that involved automated solution-phase methods. The automation process involves the use of fluorocarbon tags that can be used to pattern the surfaces of tagged molecules to form carbohydrate microarrays. Pohl spent 2019 as a Fulbright Program scholar at the University of Natural Resources and Life Sciences, Vienna.
Sources: en.wikipedia.org
τν is the spectral optical depth in frequency, and τλ is the spectral optical depth in wavelength. Although absorbance is properly unitless, it is sometimes reported in "absorbance units", or AU. Many people, including scientific researchers, wrongly state the results from absorbance measurement experiments in terms of these made-up units.
Charcot–Marie–Tooth disease was first discovered in 1886 by three scientists: Jean-Martin Charcot (1825–1893) and his assistant Pierre Marie (1853–1940), along with the English doctor Howard Henry Tooth (1856–1925). In their original publication, titled “Concerning a Special Form of Progressive Muscular Atrophy,” Charcot and Marie acknowledged that similar cases had been previously published in medical literature. Their findings described hereditary neuropathy, marked by gradual muscle wasting and diminished sensation in the extremities. This crucial discovery helped establish CMT as a distinct clinical entity, differentiating it from other neuromuscular conditions such as muscular dystrophies. Over the years, advancements in neurogenetics have led to the identification of various genetic mutations responsible for the disease, significantly enhancing our understanding of its pathogenesis and classification. Charcot also noted that prior descriptions of the disease were neither objective nor thorough. Most of the earlier accounts merely mentioned that CMT was hereditary. As a result, Charcot felt it was essential to provide a comprehensive description of the disease, ensuring that it received the attention it deserved. In 2010, Charcot–Marie–Tooth (CMT) disease became one of the first conditions in which the precise genetic cause was identified in an individual patient using whole-genome sequencing. This groundbreaking discovery was made by scientists affiliated with the Charcot–Marie–Tooth Association (CMTA).
As well as creating rights for "workers" who generally lack bargaining power in the market, the Treaty on the Functioning of the European Union also protects the "freedom of establishment" in article 49, and "freedom to provide services" in article 56. In Gebhard v Consiglio dell'Ordine degli Avvocati e Procuratori di Milano the Court of Justice held that to be "established" means to participate in economic life "on a stable and continuous basis", while providing "services" meant pursuing activity more "on a temporary basis". This meant that a lawyer from Stuttgart, who had set up chambers in Milan and was censured by the Milan Bar Council for not having registered, should claim for breach of establishment freedom, rather than service freedom. However, the requirements to be registered in Milan before being able to practice would be allowed if they were non-discriminatory, "justified by imperative requirements in the general interest" and proportionately applied. All people or entities that engage in economic activity, particularly the self-employed, or "undertakings" such as companies or firms, have a right to set up an enterprise without unjustified restrictions. The Court of Justice has held that both a member state government and a private party can hinder freedom of establishment, so article 49 has both "vertical" and "horizontal" direct effect. In Reyners v Belgium the Court of Justice held that a refusal to admit a lawyer to the Belgian bar because he lacked Belgian nationality was unjustified.
Current treatment of dermatomyositis relies on immunosuppressive agents such as corticosteroids, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, and cyclosporine, with intravenous immunoglobulin (IVIG) widely used for refractory or severe disease. Rituximab remains an important therapeutic option despite mixed clinical trial results. Emerging targeted therapies, including Janus kinase (JAK) inhibitors and agents targeting the type I interferon pathway, such as dazukibart, have demonstrated promising efficacy. Novel approaches such as CD19 chimeric antigen receptor (CAR) T-cell therapy, plasma cell–directed therapies, and neonatal Fc receptor (FcRn) inhibitors, such as efgartigimod, are also showing encouraging results, offering the potential for sustained treatment-free disease control in the case of CD19 CAR-T cell therapy. Overall, with timely diagnosis and appropriate treatment, the prognosis of DM is generally favorable. About one in 100,000 people receive a new diagnosis of dermatomyositis each year. The condition usually occurs in those in their 40s and 50s with women being affected more often than men. People of any age, however, may be affected. The condition was first described in the 1800s.
== Treatment == There is no cure for McLeod syndrome; the treatment is supportive depending on symptoms. Medication may assist with management of epilepsy, and cardiac and psychiatric features, although patients may respond poorly to treatment for chorea.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.